Topiramate for smoking cessation: Systematic review and
meta-analysis

Lotfy, Nesma; Elsawah, Hozaifa; Hassan, Mona Hassan Ahmed

doi:10.18332/tpc/115167

Cited by 6 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, Siskind 44 conducted a network meta‐analysis to explore smoking cessation effects among people with schizophrenia spectrum disorders and pointed out that Varenicline might be superior to Bupropion. As for other drugs, Lotfy 45 and David 46 synthesised the effects of Topiramate and Naltrexone on smoking cessation, respectively, with both studies indicating that these drugs have no beneficial short‐term or long‐term effects on smoking abstinence. From these systematic reviews and meta‐analyses, it can be seen that the populations studied were general smokers or smokers with schizophrenia.…”

Section: Discussionmentioning

confidence: 99%

The effects of pharmacological interventions on smoking cessation in people with alcohol dependence: A systematic review and meta‐analysis of nine randomized controlled trials

Guo¹,

Chen

et al. 2021

Int J Clin Pract

View full text Add to dashboard Cite

Background: Pharmacotherapies are widely used for smoking cessation. However, their efficacy for people with alcohol dependence remains unclear.Objective: This study aimed to explore the effects of pharmacotherapies on smoking cessation for people with alcohol dependence.Methods: Five electronic databases were searched in January 2021 for randomized controlled trials (RCTs) reporting the use of pharmacotherapies to promote smoking cessation in people with alcohol dependence. The risk of bias was assessed using the Cochrane tool. RevMan version 5.3 was used to perform meta-analyses of the changes in smoking behaviour, and the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of the evidence. Results:The search identified nine RCTs involving 908 smokers with alcohol dependence; eight were published in the USA and one in Canada. The risk of bias was low in three studies and unclear in the remaining six. The meta-analysis results showed that, compared with the placebo group, Varenicline had a significant effect on short-term smoking cessation (three RCTs, odds ratio [OR] = 6.27, 95% confidence interval [CI]:[2.49, 15.78], P < .05, very low certainty). Naltrexone had no significant effect on smoking cessation in short-term or long-term observations (three RCTs, OR = 0.99, 95% CI: [0.54, 1.81], P = .97, moderate certainty), and Topiramate had no significant effects (two RCTs, OR = 1.56, 95% CI: [0.67, 3.46], P > .05, low certainty). Only one trial reported that Bupropion did not affect smoking cessation. Conclusion:Varenicline may promote smoking cessation in people with alcohol dependence. However, Naltrexone, Topiramate and Bupropion have no clear effect on increasing smoking abstinence among drinkers. The small number of studies and the low certainty of evidence indicate that the results should be interpreted cautiously. How to cite this article: Guo K, Li J, Li J, et al. The effects of pharmacological interventions on smoking cessation in people with alcohol dependence: A systematic review and meta-analysis of nine randomized controlled trials.

show abstract

Section: Discussionmentioning

confidence: 99%

The effects of pharmacological interventions on smoking cessation in people with alcohol dependence: A systematic review and meta‐analysis of nine randomized controlled trials

Guo¹,

Chen

et al. 2021

Int J Clin Pract

View full text Add to dashboard Cite

show abstract

“…Moreover, Siskind [40] conducted a network meta-analysis to explore smoking cessation effects among people with schizophrenia spectrum disorders and pointed out that Varenicline might be superior to Bupropion. As for other drugs, Lotfy [41] and David [42] synthesized the effects of Topiramate and Naltrexone on smoking cessation, respectively, with both studies indicating that these drugs have no beneficial short-term or long-term effects on smoking abstinence. From these systematic reviews and meta-analyses, it can be seen that the populations studied were general smokers or smokers with schizophrenia.…”

Section: Comparisons With Other Studies or Reviewsmentioning

confidence: 99%

The Effects of Pharmacological Interventions on Smoking Cessation in People with Alcohol Dependence: A Systematic Review and Meta-analysis of Nine Randomized Controlled Trials

Guo

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Pharmacotherapies are widely used for smoking cessation. However, their effect on smoking cessation for people with alcohol dependence remains unclear. Objective This study aimed to explore the effects of pharmacotherapies on smoking cessation for people with alcohol dependence. Methods Five electronic databases were searched in January 2021 for randomized controlled trials (RCTs) reporting the use of pharmacotherapies to promote smoking cessation in people with alcohol dependence. The risk of bias was assessed using the Cochrane tool. RevMan version 5.3 was used to perform meta-analyses of the changes in smoking behavior, and the GRADE approach was used to assess the certainty of the evidence. Results Nine RCTs involving 908 smokers with alcohol dependence were identified. Eight RCTs were published in the United States, and one was from Canada. The risk of bias was rated as low in three studies and unclear in the remaining six. The results of the meta-analysis showed that, compared with the placebo group, Varenicline had a significant effect on short-term smoking cessation (three RCTs, OR = 6.27, 95% CI: [2.49, 15.78], p < 0.05, very low certainty). Naltrexone had no significant effect on smoking cessation in short-term or long-term observations (three RCTs, OR = 0.99, 95% CI: [0.54, 1.81], p = 0.97, moderate certainty), and Topiramate had no significant effect (two RCTs, OR = 1.56, 95% CI: [0.67, 3.46], p > 0.05, low certainty). Only one trial reported that Bupropion had no effect on smoking cessation. Conclusion Varenicline may have a positive effect on smoking cessation in people with alcohol dependence. However, Naltrexone, Topiramate, and Bupropion seem to have no clear effect on increasing smoking abstinence among drinkers. The small number of studies and the low certainty of evidence indicate that caution is required in interpreting the results.

show abstract

A Double-Blind, Placebo-Controlled Study of Adjunctive Topiramate in Adolescents With Co-Occurring Bipolar and Cannabis Use Disorders

Farrow,

DelBello,

Patino

et al. 2024

JAACAP Open

View full text Add to dashboard Cite

Topiramate for smoking cessation: Systematic review and meta-analysis

Cited by 6 publications

References 40 publications

The effects of pharmacological interventions on smoking cessation in people with alcohol dependence: A systematic review and meta‐analysis of nine randomized controlled trials

The effects of pharmacological interventions on smoking cessation in people with alcohol dependence: A systematic review and meta‐analysis of nine randomized controlled trials

The Effects of Pharmacological Interventions on Smoking Cessation in People with Alcohol Dependence: A Systematic Review and Meta-analysis of Nine Randomized Controlled Trials

A Double-Blind, Placebo-Controlled Study of Adjunctive Topiramate in Adolescents With Co-Occurring Bipolar and Cannabis Use Disorders

Contact Info

Product

Resources

About